This article is available to subscribers. Subscribe now. Already have an account? Sign in

EditorialFree Preview

Adjuvant Nivolumab in Esophageal Cancer ! A New Standard of Care

List of authors.
  • David H. Ilson, M.D., Ph.D.

Esophageal cancer is a leading cause of cancer-related illness and death throughout the world. Because there is no effective screening or early detection, most patients present with locally advanced or overt metastatic disease. Esophageal squamous-cell carcinoma is the most common histologic type worldwide in high-incidence areas such as East Asia, and adenocarcinoma is the dominant histologic type in the West. A review of surgical outcomes in nearly 84,000 patients with esophageal squamous-cell cancer in 1980 indicated the daunting challenge of treating esophageal cancer.1 Surgical exploration was performed in 58% of the patients, 39% underwent resection (30% died during or soon . . .

Funding and Disclosures

Disclosure forms provided by the author are available with the full text of this editorial at NEJM.org.

Author Affiliations

From the Breast and Imaging Center, Memorial Sloan Kettering Cancer Center, New York.